Trastuzumab  	Trastuzumab  	 NNP	B-NP
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
HER2-positive  	HER2-positive  	 CD	B-NP
metastatic  	metastatic  	 JJ	I-NP
adenocarcinoma  	adenocarcinoma  	 NN	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
stomach  	stomach  	 NN	O
or  	or  	 CC	O
gastro-oesophageal  	gastro-oesophageal  	 JJ	B-NP
junction  	junction  	 NNS	I-NP
This  	This  	 DT	O
paper  	paper  	 NN	O
presents  	presents  	 VBZ	O
a  	a  	 DT	O
summary  	summary  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
evidence  	evidence  	 NN	B-NP
review  	review  	 NN	I-NP
group  	group  	 NN	I-NP
( 	( 	 -LRB-	O
ERG 	ERG 	 NNP	O
)  	)  	 -RRB-	O
report  	report  	 NN	O
into  	into  	 IN	O
trastuzumab  	trastuzumab  	 NN	B-NP
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
human  	human  	 JJ	B-NP
epidermal  	epidermal  	 JJ	I-NP
growth  	growth  	 NN	I-NP
factor  	factor  	 NN	I-NP
receptor  	receptor  	 NN	I-NP
2  	2  	 CD	I-NP
( 	( 	 -LRB-	O
HER2 	HER2 	 NNP	B-NP
) 	) 	 -RRB-	O
-positive  	-positive  	 JJ	O
metastatic  	metastatic  	 JJ	O
adenocarcinoma  	adenocarcinoma  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
stomach  	stomach  	 NN	O
( 	( 	 -LRB-	O
mGC 	mGC 	 NNP	B-NP
)  	)  	 -RRB-	O
or  	or  	 CC	O
gastro-oesophageal  	gastro-oesophageal  	 JJ	B-NP
junction 	junction 	 NN	I-NP
.  	.  	 .	O
HER2  	HER2  	 NNP	B-NP
positivity  	positivity  	 NN	I-NP
is  	is  	 VBZ	O
defined  	defined  	 VBN	O
by  	by  	 IN	O
immunohistochemistry  	immunohistochemistry  	 NNS	B-NP
( 	( 	 -LRB-	O
IHC 	IHC 	 NNP	B-NP
) 	) 	 -RRB-	O
3+  	3+  	 NNP	O
or  	or  	 CC	O
IHC2+ 	IHC2+ 	 FW	B-NP
/ 	/ 	 FW	O
fluorescence  	fluorescence  	 FW	B-NP
in  	in  	 FW	I-NP
situ  	situ  	 FW	I-NP
hybridisation  	hybridisation  	 FW	I-NP
( 	( 	 -LRB-	O
FISH 	FISH 	 NNP	B-NP
) 	) 	 -RRB-	O
+ 	+ 	 NNP	O
.  	.  	 .	O
The  	The  	 DT	O
decision  	decision  	 NN	B-NP
problem  	problem  	 NN	I-NP
addressed  	addressed  	 NNS	O
was  	was  	 VBD	O
the  	the  	 DT	O
testing  	testing  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
whole  	whole  	 JJ	O
mGC  	mGC  	 JJ	B-NP
population  	population  	 NN	I-NP
with  	with  	 IN	O
IHC  	IHC  	 NNP	B-NP
and 	and 	 CC	O
,  	,  	 ,	O
for  	for  	 IN	O
IHC2+  	IHC2+  	 CD	B-NP
patients 	patients 	 NNS	O
,  	,  	 ,	O
also  	also  	 RB	O
with  	with  	 IN	O
FISH 	FISH 	 NNP	O
,  	,  	 ,	O
followed  	followed  	 VBN	O
by  	by  	 IN	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
HER2-positive  	HER2-positive  	 CD	B-NP
patients  	patients  	 NNS	I-NP
with  	with  	 IN	O
trastuzumab  	trastuzumab  	 VBG	O
combined  	combined  	 VBN	O
with  	with  	 IN	O
cisplatin  	cisplatin  	 NN	B-NP
and  	and  	 CC	O
either  	either  	 DT	O
capecitabine  	capecitabine  	 NN	B-NP
or  	or  	 CC	O
5-fluorouracil  	5-fluorouracil  	 NN	B-NP
( 	( 	 -LRB-	O
5-FU 	5-FU 	 NNP	B-NP
)  	)  	 -RRB-	O
[ 	[ 	 -LRB-	O
HCX  	HCX  	 NNP	B-NP
( 	( 	 -LRB-	O
trastuzumab 	trastuzumab 	 UH	B-NP
,  	,  	 ,	O
cisplatin 	cisplatin 	 NN	B-NP
,  	,  	 ,	O
capecitabine 	capecitabine 	 CD	B-NP
) 	) 	 -RRB-	O
/ 	/ 	 FW	O
fluorouracil  	fluorouracil  	 FW	B-NP
( 	( 	 -LRB-	O
F 	F 	 NNP	O
) 	) 	 -RRB-	O
]  	]  	 -RRB-	O
compared  	compared  	 VBN	O
with  	with  	 IN	O
current  	current  	 JJ	O
standard  	standard  	 JJ	O
NHS  	NHS  	 NNP	B-NP
therapy 	therapy 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
manufacturer 	manufacturer 	 NN	O
's  	's  	 POS	O
submission  	submission  	 NN	O
contained  	contained  	 VBD	O
direct  	direct  	 JJ	O
evidence  	evidence  	 NN	O
from  	from  	 IN	O
the  	the  	 DT	O
ToGA  	ToGA  	 JJ	O
trial 	trial 	 NN	O
,  	,  	 ,	O
a  	a  	 DT	O
well-conducted 	well-conducted 	 JJ	O
,  	,  	 ,	O
multinational 	multinational 	 JJ	O
,  	,  	 ,	O
phase  	phase  	 NN	O
III  	III  	 NNP	O
randomised  	randomised  	 VBD	B-NP
controlled  	controlled  	 VBN	I-NP
trial  	trial  	 NN	I-NP
( 	( 	 -LRB-	O
RCT 	RCT 	 NNP	B-NP
)  	)  	 -RRB-	O
that  	that  	 IN	O
compared  	compared  	 VBN	O
HCX 	HCX 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
F  	F  	 NN	I-NP
with  	with  	 IN	O
cisplatin  	cisplatin  	 NN	B-NP
and  	and  	 CC	O
a  	a  	 DT	O
fluoropyrimidine  	fluoropyrimidine  	 NN	B-NP
alone  	alone  	 RB	O
[ 	[ 	 -LRB-	O
cisplatin 	cisplatin 	 UH	B-NP
,  	,  	 ,	O
capecitabine  	capecitabine  	 NNS	B-NP
( 	( 	 -LRB-	O
CX 	CX 	 NNP	O
) 	) 	 -RRB-	O
/ 	/ 	 NNP	O
F 	F 	 NNP	O
] 	] 	 -RRB-	O
.  	.  	 .	O
HCX 	HCX 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
F  	F  	 NNP	I-NP
showed  	showed  	 VBD	O
statistically  	statistically  	 RB	O
significantly  	significantly  	 RB	O
better  	better  	 RBR	O
overall  	overall  	 JJ	O
survival  	survival  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
European  	European  	 JJ	O
Medicines  	Medicines  	 JJ	O
Agency-licensed  	Agency-licensed  	 JJ	O
population  	population  	 NN	B-NP
subgroup  	subgroup  	 NNS	I-NP
( 	( 	 -LRB-	O
74 	74 	 CD	O
% 	% 	 NN	O
)  	)  	 -RRB-	O
( 	( 	 -LRB-	O
hazard  	hazard  	 NN	B-NP
ratio  	ratio  	 NN	I-NP
0.65 	0.65 	 CD	O
,  	,  	 ,	O
95 	95 	 CD	O
%  	%  	 NN	O
confidence  	confidence  	 NN	B-NP
interval  	interval  	 VBD	I-NP
0.51  	0.51  	 CD	O
to  	to  	 TO	O
0.83 	0.83 	 CD	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
corresponding  	corresponding  	 JJ	O
to  	to  	 TO	O
median  	median  	 JJ	B-NP
survival  	survival  	 NN	I-NP
of  	of  	 IN	O
16  	16  	 CD	O
months  	months  	 NNS	O
versus  	versus  	 IN	O
11.8  	11.8  	 CD	O
months 	months 	 NNS	O
.  	.  	 .	O
No  	No  	 DT	O
other  	other  	 JJ	O
evidence  	evidence  	 NN	O
exists  	exists  	 VBZ	O
for  	for  	 IN	O
the  	the  	 DT	O
efficacy  	efficacy  	 NN	O
of  	of  	 IN	O
any  	any  	 DT	O
therapy  	therapy  	 NN	O
in  	in  	 IN	O
a  	a  	 DT	O
known  	known  	 VBN	O
HER2-positive  	HER2-positive  	 CD	B-NP
mGC  	mGC  	 JJ	I-NP
population 	population 	 NN	I-NP
;  	;  	 :	O
other  	other  	 JJ	O
comparisons  	comparisons  	 NNS	O
extrapolate  	extrapolate  	 VBN	O
from  	from  	 IN	O
trials  	trials  	 NNS	O
in  	in  	 IN	O
mixed  	mixed  	 JJ	O
HER2  	HER2  	 CD	B-NP
status  	status  	 NN	I-NP
populations 	populations 	 NNS	I-NP
.  	.  	 .	O
The  	The  	 DT	O
ERG  	ERG  	 NNP	O
accepted  	accepted  	 VBD	O
the  	the  	 DT	O
manufacturer 	manufacturer 	 NN	O
's  	's  	 POS	O
view  	view  	 NN	O
that  	that  	 IN	O
a  	a  	 DT	O
meaningful  	meaningful  	 JJ	O
network  	network  	 NN	B-NP
meta-analysis  	meta-analysis  	 NN	I-NP
to  	to  	 TO	O
establish  	establish  	 VB	O
a  	a  	 DT	O
comparison  	comparison  	 NN	O
for  	for  	 IN	O
HCX 	HCX 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
F  	F  	 NN	I-NP
compared  	compared  	 VBN	O
with  	with  	 IN	O
current  	current  	 JJ	O
standard  	standard  	 JJ	O
NHS  	NHS  	 NNP	B-NP
therapy  	therapy  	 NN	I-NP
[ 	[ 	 -LRB-	O
epirubicin 	epirubicin 	 UH	B-NP
,  	,  	 ,	O
cisplatin 	cisplatin 	 NN	B-NP
,  	,  	 ,	O
capecitabine  	capecitabine  	 NNS	B-NP
( 	( 	 -LRB-	O
ECX 	ECX 	 NNP	B-NP
) 	) 	 -RRB-	O
/ 	/ 	 CD	O
epirubicin 	epirubicin 	 NN	B-NP
,  	,  	 ,	I-NP
oxaliplatin 	oxaliplatin 	 NN	I-NP
,  	,  	 ,	I-NP
capecitabine  	capecitabine  	 NNS	O
( 	( 	 -LRB-	O
EOX 	EOX 	 NNP	B-NP
) 	) 	 -RRB-	O
/ 	/ 	 CD	O
epirubicin 	epirubicin 	 NN	B-NP
,  	,  	 ,	I-NP
cisplatin 	cisplatin 	 NN	I-NP
,  	,  	 ,	I-NP
5-FU  	5-FU  	 NNP	I-NP
( 	( 	 -LRB-	O
ECF 	ECF 	 NNP	B-NP
) 	) 	 -RRB-	O
]  	]  	 -RRB-	O
was  	was  	 VBD	O
not  	not  	 RB	O
possible 	possible 	 JJ	O
,  	,  	 ,	O
but  	but  	 CC	O
was  	was  	 VBD	O
unconvinced  	unconvinced  	 VBN	O
by  	by  	 IN	O
arguments  	arguments  	 NNS	O
advanced  	advanced  	 VBD	O
in  	in  	 IN	O
the  	the  	 DT	O
alternative  	alternative  	 JJ	O
narrative  	narrative  	 NN	B-NP
synthesis 	synthesis 	 NN	I-NP
.  	.  	 .	O
These  	These  	 DT	O
involved  	involved  	 JJ	O
disregarding  	disregarding  	 JJ	O
evidence  	evidence  	 NN	O
from  	from  	 IN	O
a  	a  	 DT	O
meta-analysis  	meta-analysis  	 JJ	B-NP
and  	and  	 CC	O
interpreting  	interpreting  	 VBG	B-NP
non-significant  	non-significant  	 JJ	I-NP
results  	results  	 NNS	I-NP
of  	of  	 IN	O
small  	small  	 JJ	O
RCTs  	RCTs  	 JJ	B-NP
comparing  	comparing  	 JJ	I-NP
epirubicin-containing  	epirubicin-containing  	 JJ	I-NP
triplets  	triplets  	 NN	I-NP
with  	with  	 IN	O
cisplatin 	cisplatin 	 NN	B-NP
,  	,  	 ,	O
5-FU  	5-FU  	 NNP	O
( 	( 	 -LRB-	O
CF 	CF 	 NNP	B-NP
) 	) 	 -RRB-	O
/ 	/ 	 FW	O
capecitabine  	capecitabine  	 FW	B-NP
( 	( 	 -LRB-	O
X 	X 	 NNP	O
)  	)  	 -RRB-	O
doublets  	doublets  	 NN	O
as  	as  	 IN	O
evidence  	evidence  	 NN	O
of  	of  	 IN	O
no  	no  	 DT	O
difference  	difference  	 NN	O
between  	between  	 IN	O
triplet  	triplet  	 NN	O
and  	and  	 CC	O
doublet  	doublet  	 JJ	O
regimens 	regimens 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
high  	high  	 JJ	O
CX 	CX 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
F  	F  	 NNP	I-NP
dose  	dose  	 NN	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
ToGA  	ToGA  	 JJ	O
trial  	trial  	 NN	O
was  	was  	 VBD	O
an  	an  	 DT	O
additional  	additional  	 JJ	O
basis  	basis  	 NN	O
for  	for  	 IN	O
the  	the  	 DT	O
contention  	contention  	 NN	O
of  	of  	 IN	O
equivalence 	equivalence 	 NN	O
.  	.  	 .	O
An  	An  	 DT	O
appropriate  	appropriate  	 JJ	O
de  	de  	 FW	B-NP
novo  	novo  	 FW	I-NP
economic  	economic  	 JJ	I-NP
evaluation 	evaluation 	 NN	I-NP
,  	,  	 ,	O
including  	including  	 VBG	O
an  	an  	 DT	O
economic  	economic  	 JJ	B-NP
model  	model  	 NN	I-NP
that  	that  	 WDT	O
separately  	separately  	 RB	O
compared  	compared  	 VBN	O
HCX  	HCX  	 NNP	B-NP
or  	or  	 CC	I-NP
trastuzumab 	trastuzumab 	 NN	I-NP
,  	,  	 ,	I-NP
cisplatin 	cisplatin 	 NN	I-NP
,  	,  	 ,	I-NP
5-FU  	5-FU  	 NNP	I-NP
( 	( 	 -LRB-	O
HCF 	HCF 	 NNP	B-NP
)  	)  	 -RRB-	O
with  	with  	 IN	O
the  	the  	 DT	O
triplet  	triplet  	 JJ	O
regimens  	regimens  	 JJ	O
ECX 	ECX 	 NNP	B-NP
,  	,  	 ,	O
EOX  	EOX  	 NNP	B-NP
and  	and  	 CC	O
ECF 	ECF 	 NNP	B-NP
,  	,  	 ,	O
based  	based  	 VBN	O
on  	on  	 IN	O
a  	a  	 DT	O
simple 	simple 	 JJ	O
,  	,  	 ,	O
three-state  	three-state  	 JJ	B-NP
cohort  	cohort  	 JJ	I-NP
model  	model  	 NN	I-NP
( 	( 	 -LRB-	O
progression-free 	progression-free 	 NNP	B-NP
,  	,  	 ,	O
disease 	disease 	 NN	O
,  	,  	 ,	O
progression  	progression  	 NN	O
and  	and  	 CC	O
death 	death 	 NN	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
was  	was  	 VBD	O
submitted 	submitted 	 VBN	O
.  	.  	 .	O
Utility  	Utility  	 NN	B-NP
weights  	weights  	 NNS	I-NP
were  	were  	 VBD	O
applied  	applied  	 VBN	O
to  	to  	 TO	O
estimate  	estimate  	 VB	O
quality-adjusted  	quality-adjusted  	 JJ	B-NP
life-years  	life-years  	 NN	I-NP
( 	( 	 -LRB-	O
QALYs 	QALYs 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
Costs  	Costs  	 NNS	O
were  	were  	 VBD	O
assessed  	assessed  	 VBN	O
from  	from  	 IN	O
an  	an  	 DT	O
NHS  	NHS  	 NNP	B-NP
perspective 	perspective 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
incorporated  	incorporated  	 VBN	O
the  	the  	 DT	O
acquisition  	acquisition  	 NN	O
and  	and  	 CC	O
monitoring  	monitoring  	 VBG	B-NP
costs  	costs  	 NNS	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
alternative  	alternative  	 JJ	O
regimens 	regimens 	 NN	O
,  	,  	 ,	O
HER2  	HER2  	 CD	B-NP
testing 	testing 	 NN	I-NP
,  	,  	 ,	O
adverse  	adverse  	 JJ	O
events  	events  	 NNS	O
and  	and  	 CC	O
other  	other  	 JJ	O
supportive  	supportive  	 JJ	B-NP
care  	care  	 NN	I-NP
costs 	costs 	 NNS	I-NP
.  	.  	 .	O
An  	An  	 DT	O
8-year  	8-year  	 JJ	O
time  	time  	 NN	B-NP
horizon  	horizon  	 NN	I-NP
was  	was  	 VBD	O
used  	used  	 VBN	O
to  	to  	 TO	O
represent  	represent  	 VB	O
a  	a  	 DT	O
lifetime  	lifetime  	 NN	B-NP
analysis 	analysis 	 NN	I-NP
.  	.  	 .	O
Results  	Results  	 NNS	O
from  	from  	 IN	O
the  	the  	 DT	O
ToGA  	ToGA  	 JJ	O
trial  	trial  	 NN	O
were  	were  	 VBD	O
combined  	combined  	 VBN	O
with  	with  	 IN	O
a  	a  	 DT	O
series  	series  	 NN	O
of  	of  	 IN	O
assumptions  	assumptions  	 NNS	O
on  	on  	 IN	O
relative  	relative  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
effects  	effects  	 NNS	I-NP
and  	and  	 CC	O
testing  	testing  	 NN	B-NP
strategies 	strategies 	 NNS	I-NP
.  	.  	 .	O
The  	The  	 DT	O
manufacturer 	manufacturer 	 NN	O
's  	's  	 POS	O
results  	results  	 NNS	O
produced  	produced  	 VBD	O
an  	an  	 DT	O
incremental  	incremental  	 JJ	B-NP
cost-effectiveness  	cost-effectiveness  	 JJ	I-NP
ratio  	ratio  	 NN	I-NP
( 	( 	 -LRB-	O
ICER 	ICER 	 NNP	B-NP
)  	)  	 -RRB-	O
of  	of  	 IN	O
£  	£  	 FW	O
53,010  	53,010  	 FW	O
per  	per  	 FW	O
QALY  	QALY  	 FW	B-NP
for  	for  	 FW	I-NP
HCX  	HCX  	 FW	I-NP
versus  	versus  	 FW	O
ECX 	ECX 	 FW	B-NP
.  	.  	 .	O
Although  	Although  	 IN	O
the  	the  	 DT	O
manufacturer  	manufacturer  	 NN	B-NP
undertook  	undertook  	 VBD	O
a  	a  	 DT	O
detailed  	detailed  	 JJ	O
set  	set  	 NN	O
of  	of  	 IN	O
sensitivity  	sensitivity  	 JJ	B-NP
analyses 	analyses 	 NNS	I-NP
,  	,  	 ,	O
several  	several  	 JJ	O
alternative  	alternative  	 NN	B-NP
model  	model  	 NN	I-NP
assumptions  	assumptions  	 NNS	I-NP
were  	were  	 VBD	O
not  	not  	 RB	O
evaluated 	evaluated 	 VBN	O
.  	.  	 .	O
The  	The  	 DT	O
ERG  	ERG  	 NNP	O
undertook  	undertook  	 VBD	O
a  	a  	 DT	O
series  	series  	 NN	O
of  	of  	 IN	O
alternative  	alternative  	 JJ	O
base-case  	base-case  	 JJ	B-NP
analyses 	analyses 	 NNS	I-NP
.  	.  	 .	O
As  	As  	 IN	O
a  	a  	 DT	O
result  	result  	 NN	O
of  	of  	 IN	O
these  	these  	 DT	O
analyses 	analyses 	 NN	O
,  	,  	 ,	O
EOX  	EOX  	 NNP	B-NP
replaced  	replaced  	 VBD	I-NP
ECX  	ECX  	 NNP	I-NP
as  	as  	 IN	O
the  	the  	 DT	O
appropriate  	appropriate  	 JJ	O
comparator 	comparator 	 NN	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
the  	the  	 DT	O
ICER  	ICER  	 NNP	B-NP
for  	for  	 IN	O
the  	the  	 DT	O
comparison  	comparison  	 NN	O
of  	of  	 IN	O
HCX  	HCX  	 NNP	B-NP
vs  	vs  	 VBD	O
EOX  	EOX  	 NNP	B-NP
increased  	increased  	 VBD	O
to  	to  	 TO	O
between  	between  	 IN	O
£  	£  	 NNP	O
66,982  	66,982  	 NNP	O
and  	and  	 CC	O
£  	£  	 CD	O
71,636  	71,636  	 CD	O
per  	per  	 IN	O
QALY 	QALY 	 NNP	B-NP
.  	.  	 .	O
The  	The  	 DT	O
impact  	impact  	 NN	O
of  	of  	 IN	O
implementation  	implementation  	 NN	B-NP
of  	of  	 IN	O
alternative  	alternative  	 JJ	O
testing  	testing  	 NN	B-NP
strategies  	strategies  	 NNS	I-NP
remained  	remained  	 VBD	O
unclear 	unclear 	 JJ	O
.  	.  	 .	O
There  	There  	 EX	O
is  	is  	 VBZ	O
also  	also  	 RB	O
considerable  	considerable  	 JJ	O
uncertainty  	uncertainty  	 NN	O
surrounding  	surrounding  	 VBG	O
the  	the  	 DT	O
true  	true  	 JJ	O
estimate  	estimate  	 NN	O
of  	of  	 IN	O
effectiveness  	effectiveness  	 NN	O
for  	for  	 IN	O
the  	the  	 DT	O
comparison  	comparison  	 NN	O
between  	between  	 IN	O
triplet  	triplet  	 FW	O
regimens  	regimens  	 FW	O
containing  	containing  	 FW	B-NP
epirubicin  	epirubicin  	 FW	I-NP
( 	( 	 -LRB-	O
ECX 	ECX 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
ECF 	ECF 	 NNP	I-NP
/ 	/ 	 NNP	I-NP
EOX 	EOX 	 NNP	I-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
doublet  	doublet  	 JJ	B-NP
CX 	CX 	 NNP	I-NP
/ 	/ 	 NNP	I-NP
F  	F  	 NNP	I-NP
regimens 	regimens 	 NN	I-NP
.  	.  	 .	O
Consequently 	Consequently 	 RB	O
,  	,  	 ,	O
the  	the  	 DT	O
view  	view  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
ERG  	ERG  	 NNP	O
was  	was  	 VBD	O
that  	that  	 IN	O
there  	there  	 EX	O
is  	is  	 VBZ	O
insufficient  	insufficient  	 JJ	O
evidence  	evidence  	 NN	O
on  	on  	 IN	O
the  	the  	 DT	O
efficacy  	efficacy  	 NN	O
of  	of  	 IN	O
HCX 	HCX 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
F  	F  	 NN	I-NP
compared  	compared  	 VBN	O
with  	with  	 IN	O
current  	current  	 JJ	O
NHS  	NHS  	 NNP	B-NP
standard  	standard  	 JJ	O
therapy  	therapy  	 NN	O
for  	for  	 IN	O
an  	an  	 DT	O
ICER  	ICER  	 NNP	B-NP
to  	to  	 TO	O
be  	be  	 VB	O
determined  	determined  	 VBN	O
with  	with  	 IN	O
any  	any  	 DT	O
degree  	degree  	 NN	O
of  	of  	 IN	O
certainty 	certainty 	 NN	O
.  	.  	 .	O
